Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

31.13
-0.3199-1.02%
Post-market: 31.150.0165+0.05%19:30 EDT
Volume:9K
Turnover:272.90K
Market Cap:58.22M
PE:- -
High:31.44
Open:31.38
Low:31.13
Close:31.45
52wk High:37.15
52wk Low:25.66
Shares:1.87M
Float Shares:1.87M
Volume Ratio:0.28
T/O Rate:0.47%
Dividend:0.41
Dividend Rate:1.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan

TIPRANKS
·
Sep 05

Novo Nordisk Advances New Obesity Drug NNC0721-8060 Into First Human Trial

TIPRANKS
·
Sep 05

Lilly Targets Type 1 Diabetes With New Tirzepatide Study: What Investors Should Watch

TIPRANKS
·
Sep 05

Pfizer’s Tilrekimig Eczema Trial: A Fresh Phase 3 Catalyst for PFE Investors

TIPRANKS
·
Sep 05

Pfizer’s Migraine Tablet Study Wraps Up, Supporting Pipeline Flexibility for PFE Investors

TIPRANKS
·
Sep 05

Novo Nordisk A/S Series B Stock Falls Friday, Underperforms Market

Dow Jones
·
Sep 05

Sector Update: Healthcare

MT Newswires Live
·
Sep 04

Novo Nordisk Foundation to Set Up Quantum Chip Facility

MT Newswires Live
·
Sep 04

Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase

TIPRANKS
·
Sep 04

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 04

Pfizer Announces Q3 2026 Dividend of R$ 0.37 Per Unit for Brpfizbdr 006

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03

Aspen Sees Mounjaro Africa Sales Above $124 Million in 2027

Reuters
·
Sep 03

Medicus Pharma Surges on Pfizer Licensing Deal for Experimental Cancer Therapy

Reuters
·
Sep 03

Medicus Pharma Signs Co-Development, Licensing Deal with Pfizer for Cd228v Antibody-Drug Conjugate

Reuters
·
Sep 03

Medicus Pharma - Pays Pfizer $12 Mln Upfront, $15 Mln Due on First Anniversary - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Pfizer Paid the Company a One-Time, Non-Refundable Payment of $2.0 Million

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Enters Co-Development and License Agreement with Pfizer on Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 03

Superluminal Medicines: Financing Led by Bvf Partners; Alongside Existing Investors Nvidia, Eli Lilly & Co, Cooley, and Gaingels, Among Others

THOMSON REUTERS
·
Sep 03

Rothschild & Co Redburn Adjusts PT on Eli Lilly and Co. to $930 From $915, Keeps Neutral Rating

MT Newswires Live
·
Sep 03